openPR Logo
Press release

Pipeline Assessment on Somatostatin Receptor Type 4 (SSTR4) with Analysis of Ongoing Trails Review in 2017

06-29-2017 05:17 PM CET | Health & Medicine

Press release from: Pharmaceutical Research Reports [MRH]

Pharmaceutical Industry Research Reports - MRH

Pharmaceutical Industry Research Reports - MRH

The report ' Somatostatin Receptor Type 4 (SSTR4) - Pipeline Review, H1 2017 ' outlays comprehensive information on the Somatostatin Receptor Type 4 (SSTR4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1196637

According to the recently published report 'Somatostatin Receptor Type 4 (SSTR4) - Pipeline Review, H1 2017'; Somatostatin Receptor Type 4 (SSTR4) pipeline Target constitutes close to 6 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes.

Somatostatin Receptor Type 4 (SSTR4) - Somatostatin receptor type 4 is a protein encoded by the SSTR4 gene. The activity of receptor is mediated by G proteins which inhibits adenylyl cyclase. It mediates antiproliferative action of somatostatin in tumor cells. It is functionally coupled to inhibition of adenylate cyclase and activation of both arachidonate release and mitogen-activated protein (MAP) kinase cascade.

It also reviews key players involved in Somatostatin Receptor Type 4 (SSTR4) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Preclinical and Discovery stages are 1, 1 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Hormonal Disorders, Metabolic Disorders and Oncology which include indications Chronic Pain, Acromegaly, Neuropathic Pain, Alzheimer's Disease, Cognitive Disorders, Dementia, Diabetic Retinopathy, Gastrointestinal Tumor, Neuroendocrine Tumors, Pancreatic Tumor and Pituitary ACTH Hypersecretion (Cushing Disease).

Make An Enquiry: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1196637

Scope

- The report provides a snapshot of the global therapeutic landscape for Somatostatin Receptor Type 4 (SSTR4)
- The report reviews Somatostatin Receptor Type 4 (SSTR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Somatostatin Receptor Type 4 (SSTR4) targeted therapeutics and enlists all their major and minor projects
- The report assesses Somatostatin Receptor Type 4 (SSTR4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Somatostatin Receptor Type 4 (SSTR4) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Somatostatin Receptor Type 4 (SSTR4)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Somatostatin Receptor Type 4 (SSTR4) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Browse Full Report With TOC: http://www.marketresearchhub.com/report/somatostatin-receptor-type-4-sstr4-pipeline-review-h1-2017-report.html

About Market Research Hub:

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Us

90 State Street,
Albany, NY 12207,
United States
Toll Free: 866-997-4948 (US-Canada)
Tel: +1-518-621-2074
Email: press@marketresearchhub.com
Website: http://www.marketresearchhub.com/
Read Industry News At: https://www.industrynewsanalysis.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Pipeline Assessment on Somatostatin Receptor Type 4 (SSTR4) with Analysis of Ongoing Trails Review in 2017 here

News-ID: 601516 • Views: 144

More Releases from Pharmaceutical Research Reports [MRH]

Pipeline Analysis on Phenylalanine 4 Hydroxylase Reviewed by Company, Profiled D …
Market Research Hub (MRH) has recently publicized a new study to its vast repository, which is titled as “Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 1.14.16.1) - Pipeline Review, H1 2017”. This research study outlays comprehensive information on the Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 1.14.16.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration
Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopepti …
According to the latest pipeline analysis, Aminopeptidase N (APN/CD13) acts as an exopeptidase and has been studied for decades. In recent years, it has been seen not only as a tumor-related target but also as a potential functional protein in various other physiological or pathological processes, such as analgesia, virus infection and inflammation. To elaborate further details on its global demand, a study titled “Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein
Global Indoleamine 2, 3 Dioxygenase 1 Industry Vital Pipeline Review for the Fir …
The indoleamine 2, 3 Dioxygenase 1 or IDO1 market is developing since the cancer treatment sector relies heavily on its’ in-depth research and high-quality treatments. Looking into this huge potential, a new study has been added to the vast online repository of Market Research Hub (MRH), with the title ‘’Indoleamine 2, 3 Dioxygenase 1 (Indoleamine Pyrrole 2, 3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Pipeline Review, H1 2017‘’.
Prosthetic Joint Infections - Clinical Trials Rise Due to Higher Disease Inciden …
Market Research HUB's Pharmaceutical and Healthcare latest pipeline guide Prosthetic joint infections - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Prosthetic joint infections (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news

All 5 Releases


More Releases for Somatostatin

Somatostatin Analogue Drug Market Trends, Growth, Analysis and Forecast - 2025
The global somatostatin analogue drug market is anticipated to showcase considerable growth during the forecast period (2020-2026). The rising FDA approvals, advancement in new treatment therapies, and new product launches are some of the key factors contributing to the growth of the hormone therapy replacement therapy market across the globe. According to the American Cancer Society, there are around 5,000 new carcinoid tumors diagnosed in the US each year. According
Somatostatin Analogs Market : 2020 the Year on a Positive Note
Zion Market Research analysts forecast the latest report on "Global Somatostatin Analogs Market Set for Rapid Growth, to reach Value around USD 8.38 Billion by 2025", according to their latest report the Somatostatin Analogs Market report covers the overall and all-inclusive analysis of the Somatostatin Analogs Market with all its factors that have an impact on market growth. The Somatostatin Analogs Market's complete outline is crystal clear penned down in
Somatostatin Market Top Scenario, SWOT Analysis, Business Overview & Forecast 20 …
Qyresearchreports include new market research report Somatostatin to its huge collection of research reports. The global Somatostatin market is witnessing a frequent alteration in its dynamics. Emphasizing on these changes, this research report offers an in-depth assessment of the performance of this market during the period from 2018 to 2025. In this research report, experts have determined the attractiveness of this market with the help of various significant analytical tools, such
Global Somatostatin Sales Market Report 2018
This report studies the global Somatostatin market status and forecast, categorizes the global Somatostatin market size (value & volume) by key players, type, application, and region. This report focuses on the top players in North America, Europe, China, Japan, Southeast Asia India and Other regions (Middle East & Africa, Central & South America). Free | Request Sample Copy of the Report @ https://bit.ly/2sJpTJR Somatostatin is one kind of hormone. It is widely distributed throughout
Somatostatin Receptor Market For Hormonal Disorder, Oncology, Metabolic Disorder
MarketResearchReports.Biz adds “Global Somatostatin Receptor Market Share, Size, Trends and Forecast Market Research Report” reports to its database. This report provides a strategic analysis of the Somatostatin Receptor and the growth estimates for the forecasted period. This report studies the Somatostatin Receptor Type 2 market status and outlook of global and United States, from angles of players, regions, product types and end industries; this report analyzes the top players in global
Global Somatostatin Market 2017 - UBPL, HYBIO, TianTaiShan, Shuangcheng, SAMARTH …
Apex Market Reports, recently published a detailed market research study focused on the "Somatostatin Market" across the global, regional and country level. The report provides 360° analysis of "Somatostatin Market" from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global Somatostatin industry, and estimates the future trend of Somatostatin market on the basis of